Background
Cristina Adriana Popa
ACEing the management of advanced CKD

This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond

ACEing the management of advanced CKD
Background
swapnil hiremath
BPROAD: Sprinting down the BP Road in Diabetes

This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.

BPROAD: Sprinting down the BP Road in Diabetes
news, Meta
joel topf
#HCWvsHunger 2024

Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.

#HCWvsHunger 2024
Background
Brian Rifkin
Potassium Rollercoaster Heartbreak

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

Potassium Rollercoaster Heartbreak
Background
Jade Teakell
FLOZINATing to the Future- Long Term Effects of ...

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD

diabetes

Estudio BPROAD_ El Resumen Visual

¿Puede un control intensivo de la presión arterial en pacientes con diabetes tipo 2 reducir significativamente los eventos cardiovasculares mayores? 🫀🔥

El estudio BPROAD, recientemente publicado en el NEJM, comparó los efectos de reducir la PA sistólica a menos de 120 mmHg en comparación con el estándar de menos de 140 mmHg en una población de alto riesgo.

¿Estás listo para discutir estos resultados y sus implicaciones clínicas? Veamos el resumen visual creado por @KajareeG.

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.